News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

CELLMED Research GmbH Assigns New CEO to Push Clinical Program

11/28/2011 6:58:10 AM

November 28, 2011 -- As of November 23rd 2011 CELLMED Research GmbH assigned Karl Krista, MD, MBA as CEO. Karl Krista has broad managerial experience in the life science industry and has already led the development of another cancer vaccine for the treatment of ovarian cancer. “We are very excited to have Karl Krista on board as CEO” said Wolfgang Huber, MD, MBA, president of CELLMED’s board of directors.

“We believe that his medical background, his managerial expertise from his years at McKinsey and his unique track record in cancer vaccines and ovarian cancer treatment are an excellent fit with CELLMED and will help to lead CELLMED through a successful clinical program”.

CELLMED is half way through its first clinical phase I/IIa study in ovarian cancer and is currently developing a clinical phase IIb study program with projected enrolment by the end of 2012. To implement its clinical plans, CELLMED has recently started raising € 17.8 million for a series B financing round.

“It is a great pleasure for me to be able to join CELLMED as CEO”, commented Karl Krista.

“CELLMED has turned into a highly professional and dynamic company over the past years and has a distinct focus on the clinical positioning of its unique dendritic cell vaccine to treat patients suffering from ovarian cancer, an unmet clinical need.”

CELLMED has achieved two major milestones within the past years: the start of its clinical program with its lead product PROCURE® in 2010 as well as the health authority approval of its in-house GMP processing unit for autologous cellular vaccines. PROCURE® is a dendritic cell vaccine, which is expected to stimulate the body’s own defence mechanism by eliciting both a short-term reaction against cancer cells and a long-term memory effect against future metastasis. “Our double loading concept for the comprehensive stimulation of a patient’s own immune cells is unique worldwide and patent protected”, says Wolfgang Huber.

About CELLMED Research GmbH

CELLMED Research GmbH, together with its subsidiaries “Life Research Technologies GmbH” and “Cellpro Danube GmbH”, constitutes an Austrian life science group founded in 2006. Its main focus is on the development and legal approval of its lead product PROCURE®, a patented autologous cellular immunotherapy for the treatment of ovarian cancer and other solid tumors. The uniqueness of PROCURE® is based on the double loading of dendritic cells with the universal tumor antigens Survivin and TERT. This is expected to lead to an increased immune response. The goal of the treatment with PROCURE® is to delay or ultimately prevent tumor recurrence.

CELLMED Research GmbH

Karl Krista, MD, MBA CEO

Magnesitstraße 1 3502 Krems-Lerchenfeld Austria T +43 2732 70 51

Read at

comments powered by Disqus